logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

Midea Group Co., Ltd (00300) spent RMB 31.2678 million on September 14 to repurchase 360,000 A shares.

date
16:34 14/09/2026
avatar
GMT Eight
Midea Group Co., Ltd. (00300) announced that on September 14, 2026, it spent RMB 31.2678 million to repurchase 360,000 A shares.
Midea Group Co., Ltd (00300) announced that on September 14, 2026, it spent RMB 31.2678 million to repurchase 360,000 A shares.
Related Articles
HK Stock
Anhui Conch Cement (00914) repurchased 470,000 shares for HK$7.6486 million on September 14.
HK Stock
SUN HUNG KAI CO (00086) repurchased 20,000 shares for HK$80,000 on September 14.
HK Stock
LEADS BIOLABS-B(09887): Announces Updated Phase II Clinical Study Data for Vilxin (Opatilimab, PD-L1/4-1BB Bispecific Antibody) Combined with Chemotherapy as First-Line Treatment for NSCLC in an Oral Presentation at WCLC 2026
Anhui Conch Cement (00914) repurchased 470,000 shares for HK$7.6486 million on September 14.
HK Stock
SUN HUNG KAI CO (00086) repurchased 20,000 shares for HK$80,000 on September 14.
HK Stock
LEADS BIOLABS-B(09887): Announces Updated Phase II Clinical Study Data for Vilxin (Opatilimab, PD-L1/4-1BB Bispecific Antibody) Combined with Chemotherapy as First-Line Treatment for NSCLC in an Oral Presentation at WCLC 2026
HK Stock
RECOMMEND
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
icon
10/06/2026
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
icon
10/06/2026
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
icon
10/06/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.